The DYNLL2 antibody is designed to detect DYNLL2 (Dynein Light Chain 2), a protein encoded by the *DYNLL2* gene in humans. DYNLL2 is a component of the cytoplasmic dynein complex, a motor protein critical for intracellular transport along microtubules, organelle positioning, and mitotic processes. It belongs to the dynein light chain family, which also includes DYNLL1. Unlike DYNLL1. DYNLL2 is less studied but shares structural homology and functional overlap, including roles in binding to diverse partners such as transcription factors, kinases, and apoptotic regulators. DYNLL2 is implicated in modulating cargo recruitment for dynein-mediated transport and may influence cellular processes like cell cycle progression, signal transduction, and stress response.
Antibodies against DYNLL2 are widely used in research to investigate its expression, localization, and interactions in various tissues and disease models. Studies suggest DYNLL2 dysregulation may contribute to cancer progression (e.g., breast and prostate cancers) and neurological disorders, possibly due to altered transport mechanisms or transcriptional misregulation. Researchers employ these antibodies in techniques like Western blotting, immunofluorescence, and immunoprecipitation to explore DYNLL2’s role in cellular homeostasis and pathology. Its interaction with viral proteins, such as HIV-1 integrase, also highlights its importance in host-pathogen interactions. Despite its emerging significance, further research is needed to fully elucidate DYNLL2-specific regulatory networks and therapeutic potential.